Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RARE), a biopharmaceutical company focused on the development of ...
rheumatologyadvisor8h
Setrusumab Gets Breakthrough Tx Designation for Osteogenesis Imperfecta
The FDA has granted Breakthrough Therapy designation to setrusumab to reduce fracture risk with osteogenesis imperfecta type I, III, or IV.
Zacks.com on MSN3d
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.
pharmaphorum5d
Sandoz takes aim at Amgen's Prolia/Xgeva with biosimilar
Amgen company is seeking to defend its osteoporosis franchise with UCB-partnered Evenity (romosozumab), an anti-sclerostin antibody that was approved for postmenopausal osteoporosis in 2019 and ...
Nature3d
Bone articles from across Nature Portfolio
Bone is a mineralized connective tissue from which bones, the main component of the vertebrate skeleton, are formed. Bone tissue is composed of cells, namely osteoblasts, osteoclasts and ...
rmdopen.bmj3d
Inflammation, bone loss and fracture risk in spondyloarthritis
Osteoporosis (ie, low bone mineral density) is common in ankylosing spondylitis, related to both systemic inflammation and decreased mobility. Vertebral fracture risk is increased; acute back pain in ...